Cologne, Germany, February 2, 2015
CEVEC Pharmaceuticals, the developer and licensor of the CAP® Technology, today announced a major milestone regarding its recombinant human CAP® cell derived C1 Esterase Inhibitor (C1Inh).
CEVEC´s CAP derived C1 Inhibitor material showed in a pivotal pharmacokinetic rat study a serum half life matching one of the two currently available, plasma derived treatments, Berinert®. All other known versions of recombinant C1 Inh, including e.g. Ruconest® from transgenic rabbits, displayed so far a significantly shorter half life than plasma derived C1 Inh. To achieve this excellent protein quality of the recombinant C1Inh, new glycosylation optimized CAP-GO cells were developed at CEVEC. This result, in combination with previously shown excellent specific activities of CAP derived C1 Inh and commercially attractive production yields using CAP-GO cells, paves now the way to develop a safer and more economic therapy for acute and prophylactic HAE indications.